A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
119actual
Sites
21
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-11 | actual | When the study began enrolling |
| Primary completion | 2023-11-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-07-15 | actual | When this record first appeared on the registry |
| Results posted | 2025-06-13 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Non-Small-Cell Lung
- Triple Negative Breast Cancer
Intervention
- Drug: Datopotamab Deruxtecan (Dato-DXd) — also filed as DS-1062a
Primary outcome
what the primary-completion date above is the date OFConfirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR)
measured TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-05-29 · 7.4 MB · Prot_000.pdf
Statistical Analysis Planposted 2023-08-30 · 1.2 MB · SAP_001.pdf
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed